China Foods Holdings Ltd. income statement CFOO

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, China Foods Holdings Ltd. reported revenue of $327,871, up 40.5% from the year before. It recorded a net loss of $398,672. The operating loss came to $398,923, an operating margin of -121.7%. Diluted earnings per share were -$0.02. Over the twelve months ended Jun 30, 2026, revenue was $185,871 and the net loss was $323,112. Across the 6 fiscal years shown, revenue shrank from $1.0 million in fiscal 2020 to $327,871 in fiscal 2025, about 20.2% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Sep 30, 2019	FY 2018 Sep 30, 2018	FY 2017 Sep 30, 2017	FY 2016 Sep 30, 2016
Revenue	0 -46.6%	0 +40.5%	0 +47.2%	0 -55.2%	0 -1.9%	0 -64.4%	1	—	0	0	0
Cost of revenue	0 -42.7%	0 +66.0%	0 +90.3%	0 -61.2%	0 +99.7%	0 -79.6%	1	—	0	0	0
Gross profit	0 -70.4%	0 -44.4%	0 -16.0%	0 -42.2%	0 -53.6%	0 -42.5%	0	—	0	0	0
Selling, general and administrative	0 -35.0%	0 -15.8%	1 +8.7%	0 -7.0%	1 -27.6%	1 -21.6%	1 +891.7%	0 +111.5%	0 +45.3%	0 +8.7%	0 +4.6%
Operating expenses	0 -35.0%	0 -15.8%	1 +8.7%	0 -7.0%	1 -27.6%	1 -21.6%	1	—	—	—	—
Operating income	-0 +31.3%	-0 +12.4%	-0 -12.6%	-0 -3.0%	-0 +14.0%	-0 +3.1%	-0 -426.2%	-0	—	—	—
Other non-operating income (expense)	—	0 -64.0%	0	—	—	—	—	—	—	—	—
Other income (expense)	0 -86.0%	0 -72.2%	0 -3.7%	0 -97.6%	0 +413.3%	0 -19.5%	0	—	—	—	—
Pretax income	-0 +31.2%	-0 +12.3%	-0 -12.6%	-0 -14.3%	-0 +21.3%	-0 +2.7%	-0 -415.5%	-0 -42.8%	-0 -14.3%	-0	—
Income tax	0	—	0 +1.0%	—	0 -87.6%	0 -18.8%	0 +8115.0%	—	0 +0.0%	0 +0.0%	0 +0.0%
Net income	-0 +33.6%	-0 +12.5%	-0 -12.8%	-0 -14.0%	-0 +22.3%	-0 +3.0%	-0 -424.7%	-0 -42.6%	-0 -14.3%	-0 -12.2%	-0 -8.7%
Basic EPS	-0.02 +33.6%	-0.02 +0.0%	-0.02 +0.0%	-0.02 +0.0%	-0.02 +0.0%	-0.02	—	—	—	—	—
Diluted EPS	-0.02 +33.6%	-0.02 +0.0%	-0.02 +0.0%	-0.02	—	—	—	—	—	—	—
Weighted average shares, basic	20 +0.0%	20 +0.0%	20 +0.0%	20 +0.0%	20 +0.0%	20	—	—	—	5 +0.0%	5 +0.0%
Weighted average shares, diluted	20 +0.0%	20 +0.0%	20 +0.0%	20	—	—	—	—	—	—	—
Other measures
Depreciation and amortization	0 +38.3%	0 +295.3%	0 -95.8%	0 -34.9%	0 -28.4%	0 +27.3%	0	—	—	—	—
EBITDA	-0 +32.1%	-0 +13.6%	-0 -25.3%	-0 -10.6%	-0 +10.4%	-0 +8.5%	-0	—	—	—	—
Margins
Gross margin	7.86%	9.14%	23.09%	40.48%	31.36%	66.30%	41.12%	—	—	—	—
Operating margin	-173.87%	-121.67%	-195.27%	-255.33%	-110.91%	-126.39%	-46.47%	—	—	—	—
Pretax margin	-173.84%	-121.59%	-194.88%	-254.74%	-99.76%	-124.26%	-45.53%	—	—	—	—
Profit margin	-173.84%	-121.59%	-195.24%	-254.74%	-99.99%	-126.11%	-46.34%	—	—	—	—
EBITDA margin	-170.10%	-119.54%	-194.51%	-228.58%	-92.51%	-101.21%	-39.42%	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as: CFOO (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Wanchai, Hong Kong
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1310630
Former names: Trafalgar Resources, Inc. (until Feb 20, 2019)

Other Medicinal Chemicals & Botanical Products companies

All 43 Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.